Heather Elizabeth Preston
Director/Board Member bij OXFORD NANOPORE TECHNOLOGIES PLC
Vermogen: 234 567 $ op 31-03-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Manoussos Perros | M | 56 |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 jaar |
| Mike Gutch | M | 58 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 jaar |
| Nicholas G. Galakatos | M | 66 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 8 jaar |
| Peter Bisgaard | M | 50 |
Pivotal Bioventure Partners Investment Advisor LLC
 Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | 13 jaar |
| Heather Behanna | M | 49 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 7 jaar |
| David Meek | M | 59 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 5 jaar |
| David Hastings | M | 62 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 6 jaar |
| Andrew J. Staples | M | 54 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 jaar |
| James Topper | M | 62 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 8 jaar |
| Natalie Walter | F | 50 | 5 jaar | |
| Ronald Cooper | M | 61 | 9 jaar | |
| Stuart Paynter | M | 52 | 7 jaar | |
| Jeremy Charles Green | M | 49 | 6 jaar | |
| Timothy Cowper | M | - | 12 jaar | |
| Gordon Sanghera | M | - | 19 jaar | |
| Mark W. Surber | M | - |
Avalyn Pharma, Inc.
 Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 13 jaar |
| Yair Alster | M | - |
Azura Ophthalmics Pty Ltd.
 Azura Ophthalmics Pty Ltd. Medical SpecialtiesHealth Technology Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel. | 44 jaar |
| Robert Hopfner | M | 51 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | 7 jaar |
| Donald Bergstrom | M | 52 | 3 jaar | |
| David Altarac | M | 63 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 5 jaar |
| Matthew Treagus | M | - | 3 jaar | |
| David Malek | M | 47 |
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | - |
| Nicholas Keher | M | 42 | - | |
| Kyle Dow | M | - |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | - |
| Pablo Cagnoni | M | 60 | 5 jaar | |
| Ruben Tommasi | M | 58 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 jaar |
| John Mueller | M | 64 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 jaar |
| Marc Gleeson | M | - |
Azura Ophthalmics Pty Ltd.
Azura Ophthalmics Pty Ltd. Medical SpecialtiesHealth Technology Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel. | - |
| Hannah Coote | F | - | 4 jaar | |
| Vincent Cheung | M | - |
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | 7 jaar |
| Philina Lee | M | 47 | 3 jaar | |
| Ming Cheah | M | - |
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 4 jaar |
| Rhodri Davies | M | - | 13 jaar | |
| John Schoellerman | M | - | 5 jaar | |
| Lisa Podos | F | - |
Fine Arts Museums of San Francisco
 Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Jack Strudley | M | - |
Oxford Science Enterprises PLC
 Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | 8 jaar |
| Namrata Patel | F | - | 2 jaar | |
| Alfred S. Wilsey | F | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Thomas Campbell | M | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Lyn Baranowski | F | - |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 2 jaar |
| Jack Calhoun | M | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Christopher Michael Chambers | M | 62 |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | - |
| Frederic Roch Doliveux | M | 68 | 4 jaar | |
| Adrian Hennah | M | 66 | 3 jaar | |
| Stuart Henderson | M | 66 | 8 jaar | |
| Polly Elvin | F | - |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | 4 jaar |
| Dame Davies | M | 73 | 3 jaar | |
| Carl Pascarella | M | 81 |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Jonathan Leff | M | 66 |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 7 jaar |
| Frank Mathias | M | 62 | 1 jaar | |
| Steven Gannon | M | 62 | 4 jaar | |
| Zoe McDougall | F | - | 16 jaar | |
| Tiba Aynechi | M | 48 |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 12 jaar |
| Wendy Becker | F | 58 | 3 jaar | |
| James WIllcocks | M | - | 19 jaar | |
| Clive Brown | M | - | 16 jaar | |
| Catherine Moukheibir | F | 64 | 3 jaar | |
| Barbara Duncan | F | 59 | 4 jaar | |
| Leone Patterson | F | 61 | 1 jaar | |
| Mischa Travers | M | - |
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | 2 jaar |
| Richard Scheller | M | 70 |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Aaron Tward | M | - | 2 jaar | |
| Jim Branch | M | - | 13 jaar | |
| George Marcus | M | 82 |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Andre Crawford-Brunt | M | 53 |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | 4 jaar |
| Bryan Meehan | M | 56 |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Wheeler S. Griffith | M | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Amy McKnight | F | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Frankie Jacobs Gillette | M | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Janet Barnes | F | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Ashish Khanna | M | 52 |
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | 7 jaar |
| David Hooker Spencer | M | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Belva Davis | F | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Carol Bonnie | F | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Sofia Ioannidou | M | 45 |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | - |
| Diane B. Wilsey | F | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Mark Litton | M | 56 | 14 jaar | |
| Randall Schatzman | M | 69 | 14 jaar | |
| Eric Elenko | M | 51 | 10 jaar | |
| Alan Bruce Montgomery | M | 70 |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 12 jaar |
| Chau Khuong | M | 48 | 8 jaar | |
| David A. Weber | M | 64 | 13 jaar | |
| Kevin Chow | M | 54 | 7 jaar | |
| Robert Azelby | M | 56 | 1 jaar | |
| Arthur Tzianabos | M | 60 | 4 jaar | |
| Eric Loumeau | M | 61 | 3 jaar | |
| Paul Cleveland | M | 67 | - | |
| Christopher Coughlin | M | 71 | 4 jaar | |
| David Wheadon | M | 66 | 4 jaar | |
| Iain Robert McGill | M | 51 | 7 jaar | |
| John Dawson | M | 64 | 14 jaar | |
| Andrew Heath | M | 76 | 11 jaar | |
| Peter George Lutz | M | 63 |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | 5 jaar |
| Denise Scots-Knight | M | 64 | 9 jaar | |
| James Breitmeyer | M | 70 | 5 jaar | |
| Peter John Nolan | M | 72 | 23 jaar | |
| Vickie Capps | F | 62 | 9 jaar | |
| Robert Nelsen | M | 60 | 3 jaar | |
| Lorenzo M. Tallarigo | M | 74 | 4 jaar | |
| Denice Torres | F | 64 | 4 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 63 | 63.00% |
| Verenigd Koninkrijk | 30 | 30.00% |
| Canada | 7 | 7.00% |
| Israël | 2 | 2.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Heather Elizabeth Preston
- Persoonlijk netwerk
